![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/KPL.png)
Share the post "Kwality Pharmaceuticals Limite’s Q3 2024-25 Latest News: Revenue Rises by 8.08% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 8.08 % in the past year, decrease in net sales/revenue by -6.25 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 5.99 %. Marginal increase in other income during this quarter, up by 195.05%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Kwality Pharmaceuticals Limite. Notable increase of 10.98 % in net profit Year to Year, Kwality Pharmaceuticals Limite’s profitability increased by 0.77 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 11.10 % Year to Year. EPS increased by 0.74 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 78.095 Cr | Rs. 90.034 Cr | Rs. 84.407 Cr | -6.25 % | + 8.08 % |
| Expenses | Rs. 61.41 Cr | Rs. 70.37 Cr | Rs. 66.91 Cr | -4.92 % | + 8.96 % |
| Operating Profit | Rs. 16.69 Cr | Rs. 19.66 Cr | Rs. 17.5 Cr | -10.99 % | + 4.85 % |
| OPM % | 21.37 % | 21.84 % | 20.73 % | -1.11 % | -0.64 % |
| Other Income | Rs. 0.618 Cr | Rs. 0.222 Cr | Rs. 0.655 Cr | + 195.05 % | + 5.99 % |
| Interest | Rs. 2.73 Cr | Rs. 2.71 Cr | Rs. 2.2 Cr | -18.82 % | -19.41 % |
| Depreciation | Rs. 4.82 Cr | Rs. 4.62 Cr | Rs. 4.56 Cr | -1.3 % | -5.39 % |
| Profit before tax | Rs. 9.76 Cr | Rs. 12.55 Cr | Rs. 11.4 Cr | -9.16 % | + 16.8 % |
| Tax % | 21.26 % | 32.64 % | 25.21 % | -7.43 % | + 3.95 % |
| Net Profit | Rs. 7.68 Cr | Rs. 8.46 Cr | Rs. 8.52 Cr | + 0.71 % | + 10.94 % |
| EPS in Rs | Rs. 7.39 | Rs. 8.15 | Rs. 8.21 | + 0.74 % | + 11.1 % |
Today, we’re looking at Kwality Pharmaceuticals Limite’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 8.08 %. However, it did see a marginal slip of -6.25 % from the previous quarter. Expenses decreased slightly by -4.92 % quarter-on-quarter, aligning with the annual rise of 8.96 %. Operating profit, while up 4.85 % compared to last year, faced a quarter-on-quarter dip of -10.99 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -0.64 %, but a shrinkage of -1.11 % sequentially. Other income rose by 195.05 % compared to the last quarter, despite an annual growth of 5.99 %. Interest expenses dropped significantly by -18.82 % from the previous quarter, yet the year-over-year decrease remains at a moderate -19.41 %. Depreciation costs fell by -1.3 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -5.39 %. Profit before tax grew annually by 16.8 % but saw a reduction from the preceding quarter by -9.16 %.
Tax expenses as a percentage of profits increased slightly by 3.95 % compared to last year, with a more notable quarter-on-quarter decrease of -7.43 %. Net profit rose by 10.94 % year-on-year but experienced a 0.71 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 11.1 % but a quarterly rise of 0.74 %. In summary, Kwality Pharmaceuticals Limite’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 78.095 Cr | Rs. 90.034 Cr | Rs. 84.407 Cr | -6.25 % | + 8.08 % |
| Expenses | Rs. 61.41 Cr | Rs. 70.37 Cr | Rs. 66.91 Cr | -4.92 % | + 8.96 % |
| Operating Profit | Rs. 16.69 Cr | Rs. 19.66 Cr | Rs. 17.5 Cr | -10.99 % | + 4.85 % |
| Net Profit | Rs. 7.68 Cr | Rs. 8.46 Cr | Rs. 8.52 Cr | + 0.71 % | + 10.94 % |
| EPS in Rs | Rs. 7.39 | Rs. 8.15 | Rs. 8.21 | + 0.74 % | + 11.1 % |
In reviewing Kwality Pharmaceuticals Limite’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 8.08 % year-on-year growth, although there was a slight dip of -6.25 % from the previous quarter. Expenses rose by 8.96 % compared to the previous year, with a decrease of -4.92 % quarter-on-quarter. Operating Profit surged by 4.85 % annually, and saw a -10.99 % decrease from the last quarter.
Net Profit showed yearly increase of 10.94 %, and experienced a 0.71 % increase from the previous quarter. Earnings Per Share (EPS) rose by 11.1 % annually, however rose by 0.74 % compared to the last quarter. In essence, while Kwality Pharmaceuticals Limite exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/shareholding/getty_681735120_359777.jpg)